

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class (Anticonvulsants, Corticosteroids, Others), By Drug Type (Vigabatrin, Adrenocorticotrophic Hormone, Others), By Dosage (Solid, Liquid), By Region and Competition, 2020-2030F

<https://marketpublishers.com/r/I9499CA3BFADEN.html>

Date: February 2025

Pages: 183

Price: US\$ 4,500.00 (Single User License)

ID: I9499CA3BFADEN

Abstracts

Global Infantile Spasms Therapeutics Market was valued at USD 146.34 Million in 2024 and is expected to reach USD 181.94 Million in the forecast period with a CAGR of 3.67% through 2030. The Global Infantile Spasms Therapeutics Market is witnessing steady growth, driven by the increasing prevalence of infantile spasms, a rare yet severe form of epilepsy that primarily affects infants under one year of age. The condition, also known as West syndrome, requires immediate medical intervention due to its association with developmental delays and long-term neurological complications. The market is characterized by a growing focus on early diagnosis and intervention, with healthcare providers emphasizing the importance of recognizing symptoms such as sudden, repetitive spasms. The availability of advanced diagnostic tools, including electroencephalograms (EEG) and neuroimaging, has improved detection rates, further fueling demand for effective treatment options. Pharmaceutical companies and research institutions are actively investing in novel therapies that enhance treatment efficacy while minimizing adverse effects, contributing to the market's expansion.

Rising awareness among healthcare professionals and parents about infantile spasms is playing a crucial role in the market's growth. Increased access to specialized pediatric neurology centers and improvements in healthcare infrastructure have made it easier for affected infants to receive timely treatment. The development of targeted

therapeutics, including adrenocorticotrophic hormone (ACTH), vigabatrin, and corticosteroids, has significantly improved patient outcomes. Companies are continuously innovating drug formulations to enhance efficacy and reduce side effects. The adoption of precision medicine and gene-based therapies is gaining traction, providing hope for long-term disease management. Digital health technologies, including telemedicine and artificial intelligence (AI)-based diagnostic tools, are supporting early diagnosis and remote patient monitoring, leading to improved treatment access. However, the high cost of treatment and the potential side effects of existing medications remain key challenges, impacting affordability and patient adherence.

Advancements in pediatric neurology research are creating new opportunities in the market, with pharmaceutical companies collaborating with academic institutions to develop breakthrough treatments. The emergence of novel drug delivery mechanisms, including sustained-release formulations and intranasal therapies, is expected to enhance therapeutic outcomes. Expanding government initiatives and funding for rare disease research are accelerating drug development efforts, encouraging the launch of new and effective treatment options. Patient advocacy groups and non-profit organizations are playing a significant role in raising awareness and securing financial support for affected families. The integration of biomarker-based diagnostic techniques and personalized medicine approaches is set to redefine treatment strategies, paving the way for precision-based therapies. While challenges such as regulatory hurdles and limited treatment accessibility persist, continued research and innovation in the field of pediatric epilepsy are expected to drive sustained growth in the Global Infantile Spasms Therapeutics Market.

Key Market Drivers

Advancements in Diagnostic Techniques

Infantile spasms, a rare and severe form of epilepsy predominantly affecting infants during their first year, can have devastating consequences if left untreated. Timely and accurate diagnosis is crucial for effective management, and advancements in diagnostic techniques are significantly enhancing the global infantile spasms therapeutics market.

The incidence of infantile spasms is approximately 1 in 2,920 live births. These seizures often manifest as brief, repetitive muscle contractions, which can be mistaken for normal infant movements, leading to potential delays in diagnosis. A critical diagnostic tool is the electroencephalogram (EEG), which measures brain electrical activity. Interpreting EEG findings requires expertise, as patterns associated with infantile

spasms can be subtle and easily overlooked.

Innovations in neuroimaging techniques, such as magnetic resonance imaging (MRI), have enabled healthcare providers to visualize the brain with greater clarity, identifying structural abnormalities associated with infantile spasms. Studies indicate that MRI can detect abnormalities in approximately 50% to 66% of affected children. Continuous video EEG monitoring has also revolutionized diagnosis by combining real-time video with EEG data, offering a comprehensive view of the infant's symptoms and brain activity, thus facilitating more accurate and timely diagnoses.

Key Market Challenges

Limited Awareness and Diagnosis

Limited awareness and diagnosis of infantile spasms present a significant challenge in the global infantile spasms therapeutics market. Infantile spasms are a rare but severe form of epilepsy that require immediate medical intervention to prevent long-term neurological complications. However, many parents, caregivers, and even healthcare professionals may not be fully aware of the early symptoms, leading to delayed diagnosis and treatment. The subtle nature of infantile spasms, often resembling normal baby movements or minor startles, makes it difficult for parents to recognize them as a serious neurological condition. This lack of awareness results in delayed medical consultations, which can significantly impact treatment outcomes and the long-term cognitive development of affected infants.

Healthcare professionals, particularly in regions with limited neurological expertise, may also struggle with early detection. Infantile spasms are often misdiagnosed as colic, reflux, or benign myoclonic movements, delaying the administration of appropriate therapies. Limited access to advanced diagnostic tools, such as video EEG monitoring, in rural and underdeveloped areas further exacerbates the problem. Early and accurate diagnosis is critical because timely intervention with adrenocorticotrophic hormone (ACTH), vigabatrin, or corticosteroids has been shown to improve seizure control and neurodevelopmental outcomes.

Key Market Trends

Gene Therapies

Gene therapies are emerging as a transformative trend in the global infantile spasms

therapeutics market, offering the potential for long-term disease modification rather than symptomatic relief. Infantile spasms, a rare and severe form of epilepsy, are often linked to genetic mutations, particularly in genes such as ARX, CDKL5, STXBP1, and TSC1/TSC2. Advances in gene-editing technologies, including CRISPR-Cas9 and adeno-associated virus (AAV)-based gene delivery systems, are enabling researchers to develop targeted therapies that address the underlying genetic causes of the condition. Unlike conventional treatments such as adrenocorticotrophic hormone (ACTH) and vigabatrin, which primarily aim to control seizures, gene therapies hold promise in halting or reversing disease progression at a molecular level.

Ongoing research efforts are focused on developing precise gene-editing and replacement therapies to restore normal neuronal function in affected infants. Preclinical studies have shown promising results in modifying defective genes associated with infantile spasms, potentially leading to lasting therapeutic benefits. Pharmaceutical and biotechnology companies are investing in gene therapy programs, with several candidates progressing through early-stage clinical trials. Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are providing support for orphan drug designation and expedited approval pathways for gene therapies targeting rare pediatric neurological disorders.

Despite the high cost and complexity of gene therapy development, advancements in delivery mechanisms and manufacturing processes are expected to improve accessibility over time. The growing collaboration between academic research institutions and biotech firms is accelerating the translation of gene therapies from the laboratory to clinical applications. As the understanding of the genetic basis of infantile spasms continues to expand, gene therapies have the potential to redefine the standard of care, offering a durable and potentially curative treatment option for patients who do not respond to conventional therapies. The market is witnessing an increasing shift towards personalized medicine, reinforcing the role of gene therapies in the future of infantile spasms treatment.

Key Market Players

Merck KGaA

Novartis AG

Sanofi SA

Pfizer Inc

Johnson & Johnson

Abbott Laboratories Inc

Teva Pharmaceutical Industries Ltd

Bausch Health Companies Inc.

AstraZeneca PLC

GSK PLC

Report Scope:

In this report, the Global Infantile Spasms Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infantile Spasms Therapeutics Market, By Therapeutic Class:

Anticonvulsants

Corticosteroids

Others

Infantile Spasms Therapeutics Market, By Drug Type:

Vigabatrin

Adrenocorticotrophic Hormone

Others

Infantile Spasms Therapeutics Market, By Dosage:

Solid

Liquid

Infantile Spasms Therapeutics Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia-Pacific

China

Japan

India

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infantile Spasms Therapeutics Market.

Available Customizations:

Global Infantile Spasms Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Applications
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Therapeutic Class (Anticonvulsants, Corticosteroids, Others)
 - 5.2.2. By Drug Type (Vigabatrin, Adrenocorticotrophic Hormone, Others)
 - 5.2.3. By Dosage (Solid, Liquid)
 - 5.2.4. By Region

5.2.5. By Company (2024)

5.3. Market Map

6. ASIA PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Therapeutic Class

6.2.2. By Drug Type

6.2.3. By Dosage

6.2.4. By Country

6.3. Asia Pacific: Country Analysis

6.3.1. China Infantile Spasms Therapeutics Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Therapeutic Class

6.3.1.2.2. By Drug Type

6.3.1.2.3. By Dosage

6.3.2. India Infantile Spasms Therapeutics Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Therapeutic Class

6.3.2.2.2. By Drug Type

6.3.2.2.3. By Dosage

6.3.3. Australia Infantile Spasms Therapeutics Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Therapeutic Class

6.3.3.2.2. By Drug Type

6.3.3.2.3. By Dosage

6.3.4. Japan Infantile Spasms Therapeutics Market Outlook

6.3.4.1. Market Size & Forecast

6.3.4.1.1. By Value

6.3.4.2. Market Share & Forecast

6.3.4.2.1. By Therapeutic Class

- 6.3.4.2.2. By Drug Type
- 6.3.4.2.3. By Dosage
- 6.3.5. South Korea Infantile Spasms Therapeutics Market Outlook
 - 6.3.5.1. Market Size & Forecast
 - 6.3.5.1.1. By Value
 - 6.3.5.2. Market Share & Forecast
 - 6.3.5.2.1. By Therapeutic Class
 - 6.3.5.2.2. By Drug Type
 - 6.3.5.2.3. By Dosage

7. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Therapeutic Class
 - 7.2.2. By Drug Type
 - 7.2.3. By Dosage
 - 7.2.4. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. France Infantile Spasms Therapeutics Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Therapeutic Class
 - 7.3.1.2.2. By Drug Type
 - 7.3.1.2.3. By Dosage
 - 7.3.2. Germany Infantile Spasms Therapeutics Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Therapeutic Class
 - 7.3.2.2.2. By Drug Type
 - 7.3.2.2.3. By Dosage
 - 7.3.3. Spain Infantile Spasms Therapeutics Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Therapeutic Class

- 7.3.3.2.2. By Drug Type
- 7.3.3.2.3. By Dosage
- 7.3.4. Italy Infantile Spasms Therapeutics Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Therapeutic Class
 - 7.3.4.2.2. By Drug Type
 - 7.3.4.2.3. By Dosage
- 7.3.5. United Kingdom Infantile Spasms Therapeutics Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Therapeutic Class
 - 7.3.5.2.2. By Drug Type
 - 7.3.5.2.3. By Dosage

8. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Therapeutic Class
 - 8.2.2. By Drug Type
 - 8.2.3. By Dosage
 - 8.2.4. By Country
- 8.3. North America: Country Analysis
 - 8.3.1. United States Infantile Spasms Therapeutics Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Therapeutic Class
 - 8.3.1.2.2. By Drug Type
 - 8.3.1.2.3. By Dosage
 - 8.3.2. Mexico Infantile Spasms Therapeutics Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Therapeutic Class

- 8.3.2.2.2. By Drug Type
- 8.3.2.2.3. By Dosage
- 8.3.3. Canada Infantile Spasms Therapeutics Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Therapeutic Class
 - 8.3.3.2.2. By Drug Type
 - 8.3.3.2.3. By Dosage

9. SOUTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Therapeutic Class
 - 9.2.2. By Drug Type
 - 9.2.3. By Dosage
 - 9.2.4. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Infantile Spasms Therapeutics Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Therapeutic Class
 - 9.3.1.2.2. By Drug Type
 - 9.3.1.2.3. By Dosage
 - 9.3.2. Argentina Infantile Spasms Therapeutics Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Therapeutic Class
 - 9.3.2.2.2. By Drug Type
 - 9.3.2.2.3. By Dosage
 - 9.3.3. Colombia Infantile Spasms Therapeutics Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Therapeutic Class

9.3.3.2.2. By Drug Type

9.3.3.2.3. By Dosage

10. MIDDLE EAST AND AFRICA INFANTILE SPASMS THERAPEUTICS MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Therapeutic Class

10.2.2. By Drug Type

10.2.3. By Dosage

10.2.4. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Infantile Spasms Therapeutics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Therapeutic Class

10.3.1.2.2. By Drug Type

10.3.1.2.3. By Dosage

10.3.2. Saudi Arabia Infantile Spasms Therapeutics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Therapeutic Class

10.3.2.2.2. By Drug Type

10.3.2.2.3. By Dosage

10.3.3. UAE Infantile Spasms Therapeutics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Therapeutic Class

10.3.3.2.2. By Drug Type

10.3.3.2.3. By Dosage

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Recent Developments

12.2. Product Launches

12.3. Mergers & Acquisitions

13. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Product

15. PESTLE ANALYSIS

16. COMPETITIVE LANDSCAPE

16.1. Merck KGaA

16.1.1. Business Overview

16.1.2. Company Snapshot

16.1.3. Products & Services

16.1.4. Financials (As Reported)

16.1.5. Recent Developments

16.2. Novartis AG

16.3. Sanofi SA

16.4. Pfizer Inc

16.5. Johnson & Johnson

16.6. Abbott Laboratories Inc

16.7. Teva Pharmaceutical Industries Ltd

16.8. Bausch Health Companies Inc.

16.9. AstraZeneca PLC

16.10. GSK PLC

17. STRATEGIC RECOMMENDATIONS

18. ABOUT US & DISCLAIMER

I would like to order

Product name: Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class (Anticonvulsants, Corticosteroids, Others), By Drug Type (Vigabatrin, Adrenocorticotrophic Hormone, Others), By Dosage (Solid, Liquid), By Region and Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/I9499CA3BFADEN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I9499CA3BFADEN.html>